替诺福韦酯与恩替卡韦在治疗慢性乙型肝炎的安全性与有效性的荟萃分析  

Safety and efficacy comparison between tenofovir and entecavir in treatment of chronic hepatitis B: a Meta-analysis

作　　者：尹丹萍[1] 陈春明[2] Yin Danping;Chen Chunming(Department of Disease Prevention and Contr General Hospital of Jinan Military Command,Jinan 250031,China;Department of Medical Administration,General Hospital of Jinan Military Command,Jinan 250031,China)

机构地区：[1]济南军区总医院疾病预防控制科,250031 [2]济南军区总医院医务部,250031

出　　处：《中华消化病与影像杂志（电子版）》2018年第1期24-28,共5页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

基　　金：2015年度济南军区总医院院长基金(2015QN02)

摘　　要：目的评估与比较恩替卡韦与替诺福韦酯在治疗慢性慢性乙型肝炎有效性及安全性。方法检索Pubmed/Medicine、Embase、Cochrane library数据库,恩替卡韦与替诺福韦酯治疗慢性乙型肝炎的研究,检索时间从数据库建立至2017年11月,由2名作者对检索数据进行提取与总结,运用Stata 12.0对数据进行统计学分析。结果共纳入此次荟萃分析共13篇,替诺福韦酯与恩替卡韦治疗HBV-DNA有效性方面,按照口服抗病毒药物时间,可分为2个亚组,24、48周其相对危险度与可信区间分别为:RR=1.00,95%CI(0.90~1.11),I^2=30%,P=0.152;RR=1.08,95%CI(1.00~1.16),I^2=53%,P=0.016。结论随访时间为24和48周时,在治疗慢性乙型肝炎HBV-DNA转阴率方面二者疗效相当。ObjectiveTo evaluate and compare the efficacy and safety of entecavir and tenofovir in treatment of chronic hepatitis B.MethodsThe researches on entecavir and tenofovir in treatment of chronic hepatitis B were searched in PubMed/Medicine,EMBase,Cochrane Library databases until November2017.Two authors independently extracted and summarized the data.Stata120software was used to analyze the data.ResultsA total of13studies were included in this Meta analysis.In the aspect of therapeutic effectiveness of tenofovir and entecavir for HBV DNA,the research objects were divided into two subgroups according to the use time of oral antiviral drug,and the relative risk(RR)and confidence interval(CI)of24weeks and48weeks subgroup were as follows:RR=100,95%CI(090111),I2=30%,P=0152;RR=108,95%CI(100116),I2=53%,P=0016.ConclusionTenofovir has a similar efficacy in HBV DNA negative conversion ratio compared with entecavir in follow up time24and48weeks.

关 键 词：替诺福韦酯 恩替卡韦 慢性乙型肝炎 META分析 

分 类 号：R512.62[医药卫生—内科学]